Company: Sonus Pharmaceutical
Starting stock price: $6.02
Ending stock price: $0.44
Percent Change: -92.69%
Details: Sonus was delivered a crushing blow in September. A Phase IIIÂ study of the company's breast cancer therapy, Tocosol Paclitaxel, was found to beÂ less effective and linked to more side effects than Taxol. Bayer Schering terminated it's partnership with SonusÂ on the drug in October.Â The company has since enlisted Ferghana Partners to help evaluate the company's "alternative strategies." Sonus has one other cancer drug in development.
Sonus shares shattered on drug failure. Report
Sonus shares surge as FDA approves Phase III design. Report